A Promising Step Toward Molecular Diagnosis of PJI: Are We There Yet?

Commentary Periprosthetic joint infection (PJI) remains one of the most difficult complications in arthroplasty, with diagnostic ambiguity often delaying treatment or leading to unnecessary interventions. Traditional diagnostic modalities—such as inflammatory markers, imaging, and cultures—frequently lack sensitivity and specificity, particularly in low-grade or culture-negative infections. Advanced microbiological tools such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), although more sensitive, are prone to contamination and interpretation challenges. MicroRNAs (miRNAs), small non-coding RNAs that modulate gene expression, are emerging as promising biomarkers in infection diagnostics1. They reflect host immune responses and tissue reactivity, offering a pathogen-independent signal that is both stable and quantifiable1. While previous studies have explored synovial fluid miRNAs in native-joint infections or pediatric settings, the study by Frank et al. is among the first to evaluate their role in PJI, marking a major advancement. Using a structured discovery-validation design, the authors identified 132 synovial fluid miRNAs that were differentially expressed in PJI and further investigated the 18 with the greatest differential expression. Notably, a logistic model using only 2 miRNAs yielded an area under the receiver operating characteristic curve (AUC) of 0.969. Performance was consistent across subgroups, including across culture-positive versus culture-negative infections and acute versus chronic infections. This level of accuracy is highly promising for a condition with no perfect diagnostic test. Several features distinguish this study. First, the use of synovial fluid miRNAs offers key advantages over pathogen-based diagnostics, including reduced susceptibility to contamination, superior molecular stability (making synovial fluid miRNAs suitable for biobanking and delayed testing), the need for only a small sample volume, earlier and faster detection, and greater diagnostic specificity2. Second, the authors bridged molecular diagnostics and clinical orthopaedics by leveraging transparent machine-learning models. Lastly, their findings are biologically plausible, aligning miRNA profiles with immune cell infiltration and joint-tissue response—an essential component of biomarker credibility2. The authors should be applauded for presenting not only compelling data but also a rigorous, multidisciplinary framework that can serve as a template for the future development of molecular biomarkers in orthopaedics. Their integration of clinical relevance, molecular biology, and bioinformatics elevates the impact of the study and sets a high bar for translational research in this field. However, limitations remain. All novel diagnostic tools are only as good as the standards that they are measured against. The 2018 International Consensus Meeting (ICM) criteria that were used in this study, while widely accepted, are not perfect and may affect the fidelity of model training. The study’s internal validation was methodologically sound, but external validation across diverse populations and institutions is essential in order to establish generalizability, especially in patients with comorbidities such as autoimmune diseases, diabetes, organ dysfunction, or malignancy—all of which can influence miRNA expression3. Another limitation is the lack of reported sensitivity, specificity, and predictive value metrics for all individual miRNAs or their combinations, which would have enhanced the clinical relevance. Defining cutoffs for infection versus non-infection and assessing miRNAs as standalone versus adjunctive markers remain critical future steps. Additionally, diagnostic performance in rare or complex infections—such as PJIs with fungi or atypical bacteria—was not addressed due to small subgroup sizes. The low number of hip cases (n = 22) also warrants caution in extrapolating joint-specific findings. Furthermore, the cohort was skewed toward chronic infections, potentially limiting insight into acute cases. Importantly, miRNA detection by quantitative PCR is not yet fully amenable to a point-of-care application. The turnaround time (a minimum of 2 hours) and cost may restrict its intraoperative utility, such as during second-stage reimplantation. The effect of metallosis or recent antibiotic therapy on miRNA profiles also remains unknown and should be explored in future studies. Of note, while miRNAs may aid in the diagnosis of PJI, they do not, using current methods, provide information related to pathogen identification or antibiotic susceptibility. Despite these limitations, this study represents a compelling early step toward molecular diagnostics in PJI. The authors have proposed not only a novel biomarker but also a translational roadmap—one that links immunobiology, bioinformatics, and orthopaedic practice. The concept of using host-derived miRNA signatures to diagnose infection is both elegant and practical, potentially enabling earlier, faster, more accurate, and pathogen-independent diagnostics. Broader validation, standardization of sampling and assay protocols, and economic modeling will be required before this approach can be integrated into clinical practice. We are not there yet, but this work brings us closer.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.